AMENDMENTS TO THE CLAIMS

Please amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1. (**Currently Amended**) A kit comprising a first pharmaceutical composition consisting essentially of an isolated coagulation factor IXa and a second pharmaceutical composition consisting essentially of an isolated coagulation factor VIII, wherein the first and second pharmaceutical compositions are in a sterile injectable form, and the first pharmaceutical composition contains a pharmaceutically effective amount of coagulation factor IXa, and the second pharmaceutical composition contains a pharmaceutically effective amount of coagulation factor VIII for treating haemophilia A or B when the first and second pharmaceutical compositions are administered to a patient in need of treatment for haemophilia A or B~~for simultaneous, simultaneous separate or sequential use in the treatment of haemophilia A or haemophilia B in a subject who does not present with anti-coagulation factor VIII antibodies~~.

2. (**Cancelled**)

3. (**Currently Amended**) A kit~~pharmaceutical composition consisting essentially of an isolated coagulation factor IXa~~ according to claim 1, wherein the first and second pharmaceutical compositions further comprise~~which further comprises~~ phospholipid.

4. (**Currently Amended**) A method of treating haemophilia A or haemophilia B, comprising administering by injection to a patient in need thereof a pharmaceutically effective amount of a sterile pharmaceutical composition consisting essentially of coagulation factors VIII and IXa, wherein the presence of coagulation factor IXa allows the concentration of coagulation factor VIII in the composition to be reduced in comparison to a composition which does not comprise a coagulation factor IXa.

5. (**Currently Amended**) The method according to claim 4, wherein the sterile pharmaceutical composition is administered to a patient who does not present with anti-coagulation factor VIII antibodies.

6. (**Previously Presented**) The method according to claim 4, wherein the coagulation factor VIII and IXa reagents are produced using recombinant DNA technology.

7. (**Currently Amended**) The method according to claim 4, wherein the sterile pharmaceutical composition further comprises phospholipid.

8. (**Currently Amended**) The method according to claim 4, wherein the sterile pharmaceutical composition is formulated to provide coagulation factor VIII to a subject at a dosage of between 2 and 10 IU/kg.

9-12. (**Cancelled**)

13. (**Currently Amended**) A method for potentiating coagulation factor VIII comprising the step of mixing together a pharmaceutically effective amount of coagulation factors VIII and IXa into a pharmaceutical composition, wherein the pharmaceutical composition is in a sterile injectable form.

14. (**Currently Amended**) The method according to claim 13, wherein said sterile pharmaceutical composition further comprises phospholipid.

15. (**Currently Amended**) The method according to claim 13, wherein the sterile pharmaceutical composition comprises recombinant coagulation factor IXa and recombinant coagulation factor VIII.

16-17. (**Cancelled**)

18. (**Currently Amended**) A pharmaceutical composition consisting essentially of an isolated coagulation factor VIII and an isolated coagulation factor IXa, wherein the pharmaceutical composition is in a sterile injectable form, and the pharmaceutical composition contains a pharmaceutically effective amount of coagulation factor IXa and coagulation factor VIII for treating haemophilia A or B when the pharmaceutical composition is administered to a patient in need of treatment for haemophilia A or B~~comprising the first pharmaceutical composition according to claim 1 and the second pharmaceutical composition according to claim 1~~.

19. (**New**) The kit according to claim 1, wherein the first and second pharmaceutical compositions are sterile aqueous solutions.

20. (**New**) The method according to claim 4, wherein the sterile pharmaceutical composition is a sterile aqueous solution.

21. (**New**) The method according to claim 13, wherein the pharmaceutical composition is a sterile aqueous solution.

22. **(New)** The pharmaceutical composition according to claim 18, wherein the pharmaceutical composition is a sterile aqueous solution.